158 related articles for article (PubMed ID: 32542496)
21. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
Bugatti S; De Stefano L; Bobbio-Pallavicini F; Montecucco C
RMD Open; 2020 Oct; 6(3):. PubMed ID: 33087414
[No Abstract] [Full Text] [Related]
22. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
Ingraham NE; Boulware D; Sparks MA; Schacker T; Benson B; Sparks JA; Murray T; Connett J; Chipman JG; Charles A; Tignanelli CJ
Crit Care; 2020 Apr; 24(1):182. PubMed ID: 32345336
[No Abstract] [Full Text] [Related]
23. COVID-19: an unexpected indication for anti-rheumatic therapies?
Lucchino B; Di Franco M; Conti F
Rheumatology (Oxford); 2020 Jun; 59(6):1200-1203. PubMed ID: 32374874
[No Abstract] [Full Text] [Related]
24. Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.
Painvin B; Guillot P; Verdier MC; Gacouin A; Maamar A
Intensive Care Med; 2020 Sep; 46(9):1772-1773. PubMed ID: 32514594
[No Abstract] [Full Text] [Related]
25. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
Ahn BY; Kang CK; Seo JD; Choe PG; Song SH; Park WB; Park SW; Kim NJ; Oh MD
J Korean Med Sci; 2020 Jun; 35(24):e231. PubMed ID: 32567262
[TBL] [Abstract][Full Text] [Related]
26. Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
Thomson K; Nachlis H
JAMA; 2020 Oct; 324(13):1282-1283. PubMed ID: 32870235
[No Abstract] [Full Text] [Related]
27. The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia.
Uvais NA
Prim Care Companion CNS Disord; 2020 Apr; 22(3):. PubMed ID: 32369686
[No Abstract] [Full Text] [Related]
28. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
Nina PB; Dash AP
Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
[TBL] [Abstract][Full Text] [Related]
29. US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
Shehab N; Lovegrove M; Budnitz DS
JAMA Intern Med; 2020 Oct; 180(10):1384-1386. PubMed ID: 32628242
[TBL] [Abstract][Full Text] [Related]
30. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.
Shah M; Sachdeva M; Dodiuk-Gad RP
Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251
[No Abstract] [Full Text] [Related]
31. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.
Konig MF; Kim AH; Scheetz MH; Graef ER; Liew JW; Simard J; Machado PM; Gianfrancesco M; Yazdany J; Langguth D; Robinson PC;
Ann Rheum Dis; 2020 Oct; 79(10):1386-1388. PubMed ID: 32381561
[No Abstract] [Full Text] [Related]
32. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies.
Al-Tawfiq JA; Memish ZA
Int J Antimicrob Agents; 2020 May; 55(5):105968. PubMed ID: 32259576
[TBL] [Abstract][Full Text] [Related]
34. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Estella Á; Garnacho-Montero J
Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
[No Abstract] [Full Text] [Related]
35. COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.
Halm MA
Am J Crit Care; 2020 Nov; 29(6):489-492. PubMed ID: 32839815
[No Abstract] [Full Text] [Related]
36. Audio Interview: Studying Potential Covid-19 Therapies.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(19):e72. PubMed ID: 32379957
[No Abstract] [Full Text] [Related]
37. Hydroxychloroquin for COVID-19 Why was so much hype?
Pahlajani D
J Assoc Physicians India; 2020 Aug; 68(8):94-96. PubMed ID: 32738852
[No Abstract] [Full Text] [Related]
38. [Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness].
Vollaard A; Gieling EM; van der Linden PD; Sinha B; de Boer MGJ
Ned Tijdschr Geneeskd; 2020 Jun; 164():. PubMed ID: 32749808
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic conflict in patients with COVID-19 and glaucoma.
Millá Griñó E; Muniesa Royo MJ; Pazos López M
Med Clin (Barc); 2020 Aug; 155(4):182. PubMed ID: 32591182
[No Abstract] [Full Text] [Related]
40. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?
Patrì A; Fabbrocini G
J Am Acad Dermatol; 2020 Jun; 82(6):e221. PubMed ID: 32283237
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
